This cost-utility analysis compares the cost-effectiveness of salmeterol, fluticasone propionate, combination salmeterolfluticasone, and no maintenance therapy in chronic obstructive pulmonary disease ...
PHILADELPHIA, June 1, 2021 /PRNewswire/ -- Lannett Company, Inc. (NYSE: LCI) today announced the U.S. Food and Drug Administration (FDA) has accepted the Abbreviated New Drug Application (ANDA) for ...
Vectura's partner Hikma has launched its generic version of GlaxoSmithKline’s Advair Diskus (fluticasone propionate and salmeterol inhalation powder), in dosage strengths of 100mcg/50mcg and ...
Please provide your email address to receive an email when new articles are posted on . The FDA recently issued approval to the first generic version of ...
The US Food and Drug Administration (FDA) late Wednesday approved the first generic version of GlaxoSmithKline’s Advair Diskus (fluticasone propionate and salmeterol inhalation powder) for the ...
The biggest prize is GSKs US$7 billion product Seretide/Advair. The patents on the specific combination of fluticasone propionate and salmeterol xinafoate are due to expire in 2010 in the US and in ...
Lannett has entered into an exclusive U.S. distribution agreement for Respirent Pharmaceuticals’ generic of GSK’s Flovent Diskus (fluticasone propionate powder inhaler). According to the Orange Book, ...
The U.S. Food and Drug Administration today approved the first generic of Advair Diskus (fluticasone propionate and salmeterol inhalation powder) for the twice-daily treatment of asthma in patients ...
LONDON, Dec. 17, 2020 /PRNewswire/ -- Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical company, announces it has received FDA approval for and launched its generic version of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results